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Abstract: 
 Stimulation of the occipital nerves is becoming more widely accepted in the 
treatment of occipital neuritis and migraine disorders. Presently, equipment available for 
spinal cord stimulation is adapted for insertion into the subcutaneous space over the 
occipital nerves.  Many technical factors need to be reassessed to optimize the therapy.  
We performed a retrospective review of patients implanted from 2003-2007 at a single 
center. We aimed to analyze the rate of surgical complications related to implantation 
technique. A total of 28 patients were present for analysis.  Patients were followed up to 
60 months with a mean follow up of 21 months. There is a 32% revision rate for 
electrode migration or displacement, 3.6% removal rate for infection, and a 21% removal 
rate for lack of efficacy. Although not well studied secondary to small patient 
populations, this was consistent with a review of the literature which demonstrated a 10-
60% revision rate. Other factors such as anchoring strategy, strain relief, and battery 
location were all considered in the analysis and will be presented. A major determination 
was that use of a second incision with an additional strain relief loop had only a 10% 
revision rate of the lead while those without this additional strain relief loop had a 62.5% 
revision rate. Many technical factors need to be addressed for optimization of occipital 
nerve stimulation. 
 
 
Introduction: 
The treatment of chronic neuropathic pain in the craniofacial region continues to 
be a challenge.  Peripheral nerve stimulation has been attempted to treat craniofacial pain 
for these types of patients.  Although the use of peripheral nerve stimulators is a not a 
novel concept, its use in the craniofacial region is relatively recent.   
Multiple studies have shown the effective treatment of occipital neuralgia with  
stimulation of the occipital nerve (6,7,8).  Slavin et al. have described benefits in 70% of 
the patients treated for occipital neuralgia.(6)  Similar results were reported by Melvin et 
al, in which 91% of the patients treated for C2 mediated occipital headaches reported 
reduction in medication use as well as 64% of the patients experienced reduction in the 
number of headaches (7).  Other studies have also shown the efficacy of occipital nerve 
stimulation for the treatment of migraine headaches (2,9,10).  Schwedt et al. reported that 
9 out of 15 patients (60%) treated for various chronic headache syndromes experienced a 
30% reduction in headache severity and frequency (2). In another study, 85% of patients 
with transformed migraine showed a greater than 50% reduction in frequency or severity 
of the headache after stimulation (9).  Further studies are being carried out to further 
investigate the effectiveness of occipital stimulation for other headache disorders (10). 
Equipment designed for spinal cord stimulation equipment is used for 
implantation into the occipital region over the distal branches of occipital nerves to 
induce an anti-nocioceptive effect.  Occipital nerve stimulation as such is susceptible to 
the complications that have been described with the use of spinal cord stimulators. These 
complications include, lead migration, infection, pain, as well as device failure (1).  The 
most common of these complications is lead migration and often requires surgical 
intervention (1,13,14).  In 1993, in a study by North et al. which described a 20 year 
experience ,lead migration was found in 22% of patients although the percentage of 
patients that needed surgical intervention was not disclosed. (12).  In another review of 
the literature by Ubbink et al., 14.8% of patients required surgical intervention due to 
lead migration or fracture (13).   
With occipital nerve stimulation, there has also been a significant lead migration 
requiring subsequent surgical intervention. Slavin et al. have reported 10% patients 
experiencing lead migration which required surgical intervention (6). Similarly, Melvin et 
al have reported  9% lead migration (7). Popeney et al. described a slightly higher rate at 
3/25 patients (12%) having spontaneous lead migration which required surgical 
intervention. However, in a study of 15 patients done by TJ Schwedt et al, there was a 
33% lead migration 6 months post implantation, 60% migration after 2 years, and 100% 
migration after 3 years.(2).  Due to a lack of studies with large sample size it is hard to 
quantify the percentage of patients that will experience lead migration and subsequent 
surgical intervention.       
Another serious complication is infection at the surgical site.  The rate of infection 
has ranged from 2%-10% in patients who received implantable pain therapy devices such 
as spinal cord stimulators (3,4,5). Finally other complications can occur with the device 
such as electrical failure, loss of charge, or programming issues.  
The purpose of this study is not to discuss the efficacy of occipital nerve 
stimulators, but is to analyze the rate of surgical complications related to implantation 
technique specific to occipital nerve stimulation and compare this to complication rates 
observed in the literature for peripheral nerve stimulation.  
 
Methods: 
 
After attaining institutional review board approval, a retrospectively chart review was 
performed. All patients who had undergone occipital nerve stimulation from 2003- 2007 
were included in the review. 28 patients met criteria for inclusion within the study. Ages 
ranged from 22-63 years with 25 female and 3 male patients. Average age of patients was 
41 years. Table 1 further details the patient demographics. Follow up ranged from 6-60 
months with a mean follow-up period of 21 months. The analysis was performed based 
on surgical details, complications, and reports from repeated operations. Patient 
satisfaction as well as efficacy of the stimulation was not analyzed. 
 
Implantation 
Device: The peripheral nerve system implanted consisted of an implantable pulse 
generator, as well as a percutaneous lead with use of extensions. Equipment form three 
manufacturers were used. These included Medtronic, Advanced Neuromodulation 
Systems(ANS) and ABS. All subjects initially received 2 conventionally placeable 
percutaneously wire leads with either 4 contacts or 8 contacts placed through a midline 
incision between the base of the occiput and C2. The IPG utilized was either a 8 or 16 
channel programmable device. Anchors provided by the specific manufacturer were used. 
 
Trial: 
All patients had received a pre- implantation trial. However, these trials were not all 
standardized. Twenty patients received an outpatient trial over three to five days prior to 
implantation.  Eight patients had only an on table trial.  All patients were implanted 
within 4 weeks of their trial. Those implanted with ANS(16) or ABS(4) received a trial 
prior to implantation while those with a Medtronic implant(8) had an on- table trial. All 
patients reported greater than 50 percent of headache reduction during these trials. 
 
Surgical Implantation:  
Patients were implanted either under general anesthesia or under intravenous sedation 
with local anesthesia. The patients were placed in a prone position if under general 
anesthesia or positioned in the lateral position if done under IV sedation. 
 
A midline 2cm incision was made at the level of C1 and an approximate 2cm 
subcutaneous pocket was created above and visualizing the occipital cervical fascia. A 
Touhy needle was advanced laterally on the skull from the midline incision in a trajectory 
over the occipital nerve.  If the patient were under general anesthesia, the trajectory was 
determined by insonating the occipital artery aiming the Touhy needle across that region 
(16, 17).  If the patient were under sedation, awake testing was performed to test for 
maximal stimulation of the occipital region during intra-operative testing.  Multiple 
repositions were potentially performed to achieve this. The needle was used to place the 
lead. The lead was then secured via an anchor placed proximal to the electrode. The 
anchor was secured to the fascia and to the electrode with two neurolon sutures.  In every 
case, a strain relief loop was tucked into the subcutaneous fascia after creating an area 
with less tension. 
 The IPG was then placed via an incision in the buttocks, chest, or abdomen and 
the location was determined based on the patient’s preference. Leads were tunneled to an 
extension when needed.  Later in the learning curve, a paraspinal incision was added and 
an additional subcutaneous pocket was created in the region around C7- T1 where an 
additional strain relief loop was placed and secured with a stitch. There was then further 
tunneling to the IPG. Incisions were then closed in two layers. The patient were all taken 
to the recovery room and subsequently discharged home on the same day. 
 
Results: 
 
Twenty-eight patients were included for evaluation. Follow up was 2-60 months with a 
mean of 21 months. Follow up included office visits at 1 week, 1 month, 1 year, and 2 
years with X-rays for evaluation as well as any additional needed office visits.  Age of 
patients ranged from 22-63 years with 25 female and 3 male patients. Average age of 
patients was 41yo.  
 
 
The most common adverse event was lead migration (Table1). This was observed in 7 of 
the 28 patients and they were all females.  In fact, there were a total of 13 revisions 
surgeries in those 7 patients. This was observed over the continuum of the 60 month 
follow up period demonstrating it to be a phenomenon seen well after the acute period of 
implantation. There was a 26 week average time to revision with 54% requiring revision 
within 8 weeks, 39% within 4 weeks and 31% within 2 weeks. All 13 lead migration 
required surgical revision. It is of importance to note that only 3 of the observed lead 
migrations (23% of the migrations) were secondary to documented traumas which lead to 
the displacement of the leads. One of these was a facial trauma which caused 
hyperextension of the neck and a broken lead. Another was a fall while standing into a 
door causing flexion- rotation of the neck which caused displacement of the lead. While 
the third was observed after a motor vehicle accident. In all patients treated for migration 
the effectiveness of the stimulator was restored after revision and no residual side-effects 
were noted. 
 
Over time the surgical technique was modified to include an additional strain relief loop 
placed via a second incision in the cervical-thoracic paraspinal region. Use of a second 
incision with an additional strain relief loop had a 10% revision rate of the lead while 
those without this additional strain relief loop had a 62.5% revision rate. The two 
revisions (10%) noted with a second strain relief loop were also observed only after 
documented trauma. The revision rate with those patients undergoing a second strain 
relief loop excluding trauma would be 0% in the current review. 
 
 
Initial electrode revision for migration was noted in 7 patients or 25% of total patients. 
Five of these seven patients would undergo revision surgery again for electrode revision 
(71%). Repeat revisions were only noted in those patients undergoing placement without 
a second strain relief loop. Of note the two others not requiring a repeat revision were 
patients who had initially been placed with a second strain relief loop but sustained a 
trauma. 
  
Other adverse events included infection. Five of the 28 patients (17.9%) developed signs 
of an infection. Four of the 5 patients (14.3%) were successfully treated with PO 
antibiotics with follow up in the office Two of the four patients treated with PO 
antibiotics were at the IPG site (one abdomen, one buttock) while another was at the 
cervical incision and the last was at the second incision lateral to C7-T1.  One patient 
(3.6%) required removal of the electrode and IPG with replacement in 2 months after a 6 
week course of IV antibiotics. This patient had erosion of the wires through the skin of 
her back.   
 
In 6 patients (21%) the stimulator was removed for lack of efficacy. 5 of these 6 patients 
felt that the stimulation was not effective while the sixth did not like the 
sensation/parasthesias accompanying the stimulation. The degree of efficacy and patient 
satisfaction with the stimulation is not evaluated in this study.   
 
Two patients(7.1%) were noted to have persistent pain at the incisional sites.  One patient 
described pain in the cervical region which did not require surgical correction. The 
anchors appeared to become palpable through the skin.  The other patient (3.6%) was 
noted to have pain at the battery site in the buttock.  This patient even underwent 
repositioning of the battery to the abdomen but still continues to have pain at the battery 
site despite surgical re-exploration of that site.  Incidentally, he is still continuing to use 
his neural stimulation system to date. 
 
Four patients were noted to have pain at their battery site. Three of these were in the 
buttock from which there were 21 implants (14.2%) while one was in the chest for which 
there were 5 implants (20%). Two of the three batteries placed in the buttock that had 
pain required surgical revision. There were a total of 4 abdominal battery placements, of 
which two were after revision from initial buttock placement. None of these patients 
reported pain at their battery site. 
 
Battery revision for migration was also noted. There was one migration in the chest (20% 
of chest implants) as well as one migration in the buttock (4.8% of buttock implants). 
Therefore there is a 7.1% battery migration rate noted across all patients and battery 
placements. Migration was not noted in the four abdominal implants. 
 
Of the remaining surgeries performed there was an IPG change in 4 patients (14%) for 
end of life of the battery. There was also a revision of the IPG secondary to malfunction 
of the battery in 1 patient (3.6%). This was observed after a fall in which the patient 
landed on the battery. There was also a revision of the lead secondary to malfunction in 1 
patient (3.6%). 
 
In the 28 patients there were a total of 59 surgeries performed including those in 
reference to the battery, while there was 41 surgeries total in reference to the leads. Each 
patient underwent between 1 and 5 surgeries in the follow up period of 60 months. 
Analyzing this data demonstrates that on average there was 2.1 surgeries per patient in a 
60 month follow up period. 
 
Discussion: 
Occipital nerve stimulation is now being investigated for the treatment of chronic 
headache syndromes (2, 7, 9, 10). Additionally, multiple previous studies have shown the 
effective treatment of occipital neuralgia with peripheral stimulation of the occipital 
nerve (6,7,8). The effectiveness of therapy will be dependent on patient population and 
disease entity being treated and hopefully borne out in prospective clinical trials.  
However, the effectiveness of the therapy is highly also influenced by its surgical 
complications. 
 
Occipital nerve stimulation can share some of the various complications that arise with 
the use of spinal cord stimulators. These complications include lead migration, infection, 
as well as device failure (1).  The most common of these complications is lead migration 
which has also been reported with spinal cord stimulators and this often requires surgical 
intervention (1, 13, 14).  The revision rate for peripheral nerve stimulation appears to be 
higher than those rates observed for spinal cord stimulation (2, 6, 7, 12, 13). In a study of 
15 patients with occipital nerve stimulation done by Schwedt et al, there was a 33% lead 
migration 6 months post implantation, 60% migration after 2 years, and 100% migration 
after 3 years.(2).  Schwedt et al commented that surgical revision may be more common 
after an adequate length of follow up. However, it is expected that most patients will have 
lead migration requiring revision within 1 year of implantation. Oh et al found a 70% 
revision rate for migration in occipital nerve stimulators within the first 6 weeks of 
implantation (15). In this paper they believe that the use of percutaneous cylindrical 
electrodes led to electrode migration secondary to anchor dislodgement from recurring 
skull base spasm. Other papers have also commented on higher rates of migration with 
the use of cylindrical electrodes in the high cervical region (9, 14).  It was therefore felt 
that use of a paddle style electrode was less likely to migrate secondary to the ability for 
easier and more effective suturing or anchoring to the fascia or subcutaneous tissue (15). 
 
In the current series, the most common adverse event was lead migration (Table1). These 
were seen in 7 of the 28 patients followed for a total of 13 revisions within 41 surgeries 
(32%). This was observed over the continuum of the 60 month follow up period 
confirming  that lead migration may be seen in most patients in the acute period but may 
also occur over extended periods of follow up. It is of importance to note that 3 of the 
observed lead migrations (23% of the migrations) were secondary to documented traumas 
which lead to the displacement of the leads. 
 
Methods of implantation and anchoring differ among surgeons. There is an evolution 
over time that leads to changes in technique for anchoring as well as positioning of the 
electrode. Important distinctions can be made on the choice of suturing to the 
subcutaneous tissue versus the cervical fascia. Placement and methods of stress relief of 
the leads can also effect the amount of lead migration sustained. Lastly the location and 
placement of the IPG can change degree of strain on the electrode when considering 
angle and direction of tunneling as well as distance from the electrode site. 
 In this series, the use of an additional strain relief loop through a separate incision 
dramatically reduced the lead migration and revision rate. Patients with an additional 
strain relief loop had only a 10% revision rate of the lead while those without this 
additional strain relief loop had a 62.5% revision rate. Furthermore, the two revisions 
(10%) noted with a second strain relief loop were also observed after a documented 
trauma leading to the assumption that without associated trauma the revision rate would 
be much lower.  
  
It has been observed that there is less migration rates when using a midline incision as 
oppose to a lateral incision (7). A midline incision dictates the use of two electrodes if 
there is a need for bilateral stimulation. A single electrode can be used to span both 
occipital nerves if a lateral incision is utilized.  However it is felt that use of the midline 
incision will allow more effective placement, ease of placement, and a greater ability to 
anchor the electrode in a position that allows minimal migration, if any. Use of two 
electrodes will also allow a greater area of coverage that cannot be obtained via a single 
electrode that spans both occipital nerves. 
 
Some patients were noted to have pain at their battery site. The majority of these were 
noted with placement in the buttock. Two of the three batteries placed in the buttock that 
had pain required surgical revision (7.1% total or 9.5% of buttock). There were a total of 
4 abdominal battery placements, of which two were after revision from initial buttock 
placement. None of these patients reported pain at their battery site. Although a small 
number this suggests that patients tolerate placement of the IPG in the abdomen over the 
buttock. It did not appear in our study to affect migration or revision rates. The drawback 
to abdominal placement of the IPG is that it necessitates placement in the lateral position 
in the operating room as oppose to prone when undergoing buttock placement. 
 
Each patient underwent between 1 and 5 surgeries in the follow up period of 60 months. 
Analyzing this data demonstrates that on average there was 2.1 surgeries per patient in a 
60 month follow up period. One potential area of improvement is the type of equipment. 
PNS systems are usually modified forms of spinal cord stimulation equipment. Although 
there is interchangeability among the two it has become more evident that use of this 
equipment has different rates of migration between use as a PNS and a SCS. It is 
therefore feasible that with new equipment and technology we can limit the lead 
migration rate by designing systems that are more specific to PNS. More specifically 
stimulation in the cervical region leads to cervical tension as well as skull base spasm that 
is not seen in other sites of PNS and this has to be taken into account when considering 
causes of anchor dislodgement. 
 
Another serious complication is infection at the surgical site.  Historically, the rate of 
infection has ranged from 2%-10% in patients who received implantable pain therapy 
devices such as spinal cord stimulators (3,4,5). Our data showed a 3.6% removal rate for 
infection and 17.9% overall rate of infection. 4 of the 5 patients (14.3%) were 
successfully treated with oral antibiotics with follow up in the office. Two of the four 
patients treated with oral antibiotics were at the IPG site while another was at the cervical 
incision and the last was at the second incision lateral to C7-T1. There did not seem to be 
a common factor, such as location of battery or placement of leads that lead to infection. 
This is consistent with published data and seems to be interchangeable among SCS and 
PNS. 
  
Conclusion:  
The rate of surgical revision with occipital nerve stimulators remains high. This may be 
largely a factor of the differences in surgical techniques. A paddle style electrode 
implanted via a midline incision may be effective in lowering this rate.  Additionally, 
better anchoring to the cervical fascia and the use of an second strain relief loop at the 
cervical-thoracic junction may overcome the cervical tension imposed on the electrodes.  
A consensus statement among implanting physicians critically analyzing the factors in 
surgical technique to minimize complications is due.  Overtime if there is not a change in 
this rate of revision it will be interesting to evaluate if the effectiveness of occipital nerve 
stimulation as a treatment modality for various syndromes out weights the multiple 
surgeries required to maintain its sustainability.  Finally, hardware related pain requiring 
re-operation will also need to be addressed by the manufacturers. 
 
 
 
Table 1a: Incidence of Adverse Events 
Adverse Event Number of Patients Surgical Revision 
Rate of 
Revision 
Lead Migration 
7 patients/13 
revisions Yes 32% 
Lead Migration secondary to 
Trauma 3 Yes 
23% of 
migrations 
Battery Migration 2 Yes 7.1% 
Infection-PO antibiotics 4 No 14.3% 
Infection-IV antibiotics 1 Yes 3.6% 
Lack Of Efficacy 6 Yes 21% 
Malfunction(Lead) 1 Yes 3.6% 
Malfunction(Battery) 1 Yes 3.6% 
EOL battery 4 Yes 14% 
 
 
Table 1b: Breakdown of Lead Migrations 
 
Number of 
Patients(First Revision) Percentage 
Number of Patients 
Requiring Repeat 
Revisions after First Percentage 
Total Patients 28 100% 5 17.9% 
Total Lead 
Revisions 7 25% 5 patients(6 revisions) 71% 
Patients with 
Strain Relief 
Loop 20 71.5% 0 0% 
Strain relief loop 
patients with lead 
migration 
2- (Both included 
trauma) 
10% (7.1% of 
total patients) 0 0% 
Patients without 
Strain Relief 
Loop 8 28.5% 5 71% 
Without strain 
relief loop 
patients with lead 
migration 5 
62.5% (17.9% 
of total 
patients) 6 revisions 85% 
 
 
Table 1c: Other Events 
 Number Percentage 
Buttock IPG Placement 21 75% 
Chest IPG Placement 5 17.9% 
Abdomen IPG 
Placement 2 initial/4 total 7.1% 
Pain at IPG(Total) 4 14.3% 
Pain at IPG(Buttock) 3 19.0% 
Pain at IPG(Chest) 1 20.0% 
Pain at IPG(Abdomen) 4 0.0% 
Battery Revision for 
Pain(Total) 2 7.1% of total 
Battery Revision for 
Pain(Buttock) 2 
9.5% of Buttock 
placement 
Pain at Electrode 1 3.6% 
Electrode Revision For 
Pain(at buttock incision) 1 3.6% 
 
 
 
Table 2: Demographics 
Total Number of Patients 28, ANS(16) Medtronic(8) ABS(4) 
Year of Implant 2003- 2007 
Gender 25 Female,  3 Male 
Mean Age(range) 41years (22-63years) 
Average Follow up(range) 21 months (6-60 months) 
Average Number of 
Surgeries(total) 2.1 (59) 
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